Detalhe da pesquisa
1.
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
JAMA
; 329(9): 745-755, 2023 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36881031
2.
Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient.
Ann Hematol
; 102(8): 2283-2284, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183208
3.
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
JAMA Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696205
4.
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Transplant Cell Ther
; 29(3): 208.e1-208.e6, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36584941
5.
Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia.
medRxiv
; 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577695
6.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Transplant Cell Ther
; 28(4): 187.e1-187.e10, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081472
7.
Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents.
Clin Med Insights Blood Disord
; 14: 2634853521999389, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33716516
8.
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
J Clin Oncol
; 39(18): 1971-1982, 2021 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33905264